Literature DB >> 23578885

Monogenic diseases that can be cured by liver transplantation.

Stefano Fagiuoli1, Erica Daina, Lorenzo D'Antiga, Michele Colledan, Giuseppe Remuzzi.   

Abstract

While the prevalence of most diseases caused by single-gene mutations is low and defines them as rare conditions, all together, monogenic diseases account for approximately 10 in every 1000 births according to the World Health Organisation. Orthotopic liver transplantation (LT) could offer a therapeutic option in monogenic diseases in two ways: by substituting for an injured liver or by supplying a tissue that can replace a mutant protein. In this respect, LT may be regarded as the correction of a disease at the level of the dysfunctional protein. Monogenic diseases that involve the liver represent a heterogeneous group of disorders. In conditions associated with predominant liver parenchymal damage (i.e., genetic cholestatic disorders, Wilson's disease, hereditary hemochromatosis, tyrosinemia, α1 antitrypsin deficiency), hepatic complications are the major source of morbidity and LT not only replaces a dysfunctional liver but also corrects the genetic defect and effectively cures the disease. A second group includes liver-based genetic disorders characterised by an architecturally near-normal liver (urea cycle disorders, Crigler-Najjar syndrome, familial amyloid polyneuropathy, primary hyperoxaluria type 1, atypical haemolytic uremic syndrome-1). In these defects, extrahepatic complications are the main source of morbidity and mortality while liver function is relatively preserved. Combined transplantation of other organs may be required, and other surgical techniques, such as domino and auxiliary liver transplantation, have been attempted. In a third group of monogenic diseases, the underlying genetic defect is expressed at a systemic level and liver involvement is just one of the clinical manifestations. In these conditions, LT might only be partially curative since the abnormal phenotype is maintained by extrahepatic synthesis of the toxic metabolites (i.e., methylmalonic acidemia, propionic acidemia). This review focuses on principles of diagnosis, management and LT results in both paediatric and adult populations of selected liver-based monogenic diseases, which represent examples of different transplantation strategies, driven by the understanding of the expression of the underlying genetic defect.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Genetic diseases; Inborn; Liver transplantation; Metabolic diseases; Rare diseases; Surgical gene therapy

Mesh:

Year:  2013        PMID: 23578885     DOI: 10.1016/j.jhep.2013.04.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  36 in total

Review 1.  Concise Review: Updated Advances and Current Challenges in Cell Therapy for Inborn Liver Metabolic Defects.

Authors:  Mustapha Najimi; Florence Defresne; Etienne M Sokal
Journal:  Stem Cells Transl Med       Date:  2016-05-31       Impact factor: 6.940

2.  Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I.

Authors:  L Bočkor; G Bortolussi; A Iaconcig; G Chiaruttini; C Tiribelli; M Giacca; F Benvenuti; L Zentilin; A F Muro
Journal:  Gene Ther       Date:  2017-08-14       Impact factor: 5.250

Review 3.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

4.  Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.

Authors:  Alessia De Caneva; Fabiola Porro; Giulia Bortolussi; Riccardo Sola; Michela Lisjak; Adi Barzel; Mauro Giacca; Mark A Kay; Kristian Vlahoviček; Lorena Zentilin; Andrés F Muro
Journal:  JCI Insight       Date:  2019-06-18

Review 5.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 6.  Organic acidurias in adults: late complications and management.

Authors:  Ali Tunç Tuncel; Nikolas Boy; Marina A Morath; Friederike Hörster; Ulrike Mütze; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2018-01-15       Impact factor: 4.982

7.  Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation.

Authors:  Neslihan Celik; Beau Kelly; Kyle Soltys; James E Squires; Jerry Vockley; Diana A Shellmer; Kevin Strauss; Patrick McKiernan; Armando Ganoza; Rakesh Sindhi; Geoffrey Bond; George Mazariegos; Ajai Khanna
Journal:  Clin Transplant       Date:  2019-10-06       Impact factor: 2.863

Review 8.  Connexin and pannexin signaling in gastrointestinal and liver disease.

Authors:  Michaël Maes; Sara Crespo Yanguas; Joost Willebrords; Bruno Cogliati; Mathieu Vinken
Journal:  Transl Res       Date:  2015-05-16       Impact factor: 7.012

9.  Perioperative characteristics and management of liver transplantation for isolated methylmalonic acidemia-the largest experience in China.

Authors:  Yi-Zhou Jiang; Li-Ying Sun; Zhi-Jun Zhu; Lin Wei; Wei Qu; Zhi-Gui Zeng; Ying Liu; Yu-Le Tan; En-Hui He; Rui-Fang Xu; Liang Zhang; Jun Wang; Xiao-Jie Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

10.  Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome.

Authors:  Giulia Bortolussi; Lorena Zentillin; Jana Vaníkova; Luka Bockor; Cristina Bellarosa; Antonio Mancarella; Eleonora Vianello; Claudio Tiribelli; Mauro Giacca; Libor Vitek; Andrés F Muro
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.